| Autor: |
Iizuka, Yoshikazu, Aiso, Masumi, Ohshima, Toshiteru, Sawada, Shigemasa, Horie, Takashi |
| Zdroj: |
Medical Oncology & Tumor Pharmacotherapy; Jun1992, Vol. 9 Issue 2, p57-64, 8p |
| Abstrakt: |
We have measured the serum levels of soluble CD4, CD8 and IL-2R in 43 patients with AML in complete remission (AML-CR). The sCD8 levels of AML-CR patients (443.9 ± 224.4 u/ml) were significantly high as compared to that of the normal controls (177.1 ± 76.3 u/ml), p < 0.01. The sIL-2R levels of AML-CR patients were 715.0 ± 646.3 u/ml, which significantly differed when compared to 322.1 ± 65.7 u/ml for the normal controls, p < 0.01. However, the sCD4 levels of AML-CR patients were 9.6 ± 4.7 u/ml, which did not differ from the 8.3 ± 2.6 u/ml of the normal controls. The AML-CR patients showed significantly increased sCD8 and sIL-2R levels at all ranges during the remission from one to 188 months. The sCD8 levels and sIL-2R levels of the AML-CR patients showed a close correlation, p < 0.01. Further, the sCD8 levels and lymphokine activated killer cell cytotoxic activity showed a close correlation, p < 0.05. The presence of the activation of anti-tumor immunity may be related to the continuance of the remission in the AML-CR patients. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
